than January 2, 1998. Requests for further information may also be forwarded to this address.

SUPPLEMENTARY INFORMATION: The GSA is anticipating the preparation of an Environmental Impact Statement on a proposal to dispose of excess federal property in New York, New York. GSA will serve as the lead agency and scoping will be conducted consistent with NEPA regulations and guidelines.

GSA invites interested individuals, organizations, and Federal, State, and local agencies to participate in defining the reasonable alternatives to be evaluated in the EIS, and in identifying any significant social, economic, or environmental issues related to the alternatives. During scoping, comments should focus on identifying specific impacts to be evaluated and suggesting alternatives that minimize adverse significant impacts while achieving similar objectives. Comments may also identify issues which are not significant or which have been covered by prior environmental review. Scoping should be limited to commenting on alternatives and the merit of the proposal rather than indicating preferences. There will be an opportunity to comment on preferences upon completion of the Draft Environmental Impact Statement (DEIS).

Mailing List: If you wish to be placed on the project mailing list to receive future or further information as the EIS develops, contact Peter A. Sneed at the address noted above.

Project Purpose, Historical Background, and Project: On October 16, 1995, the United States Coast Guard (USCG) announced it would close Governors Island by the end of summer 1997. The decision to close Governors Island was made in response to the Presidential mandate to meet the goals of the National Performance Review and the Government Performance and Results Act. The present organization of Governors Island will transition to a 60-person Caretaker Detachment that will provide security, fire protection and facility maintenance. Disposal of the Island is the responsibility of the General Services Administration. On August 5, 1997, President Clinton signed into law, legislation for the sale of Governors Island. This special legislation incorporated as part of the Balanced Budget Act of 1997 directs the Administrator of General Services Administration to sell Governors Island at fair market value. The State and City of New York have right of first offer to purchase all or part of the Island at fair market value.

Alternatives: The EIS will examine the short and long term impacts on the natural and built environment. Potential impact assessment will include but not be limited to changes in land use and zoning, changes to air and water quality, changes to traffic patterns, and impacts to historic and cultural resources.

The EIS will also examine measures to mitigate significant unavoidable adverse impacts resulting from the proposed action. Concurrent with NEPA implementation, GSA will also implement its consultation responsibilities under Section 106 of the Natural Historic Preservation Act to identify potential impacts to existing historic or cultural resources.

The EIS would consider a no-action alternative and an action alternative which would identify several reuse options. The no-action alternative (no-sale) would keep Governors Island in Federal ownership. The preferred action alternative is the sale of Governors Island.

Procedures: The Draft EIS will be prepared at the completion of and based upon a scoping report. The Draft EIS will then be made available for public and agency review and comment with a public hearing being held during this comment period. A Final EIS would be prepared following conclusion of the comment period to address issues raised on the Draft EIS.

Dated: November 28, 1997.

Robert Martin,

Acting Regional Administrator (2A).

[FR Doc. 97–31858 Filed 12–4–97; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request Proposed Projects

Title: Interim Tribal TANF Data Report.

OMB No.: New Collection.

Description: This information is being collected to meet the statutory requirements of section 411 of the Social Security Act and section 116 of the Personal Responsibility and Work Opportunity Reconciliation Act of 1996. It consists of desegregated demographic and program information that will be used to determine participation rates and other statutorily required indicators for the Tribal Temporary Assistance for Needy Families (Tribal TANF) program.

Respondents: Tribal Governments.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
TANF Data Report ..... Estimated Total Annual Burden Hours: 32,472	18	4	451	32,472

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including though the use of automated collection techniques or other forms of information technology. Consideration will be given to

comments and suggestions submitted within 60 days of this publication.

Dated: November 25, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–31855 Filed 12–4–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0480]

Zenith Goldline Pharmaceuticals; Withdrawal of Approval of 11 Abbreviated Antibiotic Applications and 105 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 11 abbreviated antibiotic applications (AADA's) and 105 abbreviated new drug applications (ANDA's). Zenith Goldline Pharmaceuticals notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: January 5, 1998.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: Zenith Goldline Pharmaceuticals, 140 Legrand Ave., Northvale, NJ 07647, has informed FDA that the drug products listed in the following table are no longer marketed and has requested that FDA withdraw approval of the applications. Zenith Goldline Pharmaceuticals has also, by its request, waived its opportunity for a hearing.

Application No.	Drug
AADA 60–072	Penicillin G Potassium Powder, 100,000 units/5 milliliters (mL), 200,000 units/5 mL, 250,000 units/5 mL, 400,000 units/5 mL, 500,000 units/5 mL
AADA 60–073	Penicillin G Potassium Tablets USP, 100,000 units/Tab, 200,000 units/Tab, 250,000 units/Tab, 400,000 units/Tab, 500,000 units/Tab
AADA 60–104	Chlortetracycline Hydrochloride (HCl) Capsules USP, 250 milligrams (mg)
AADA 60–518	Penicillin V Potassium Tablets USP, 125 mg, 250 mg, 500 mg
AADA 60–519	Penicillin V Potassium Powder, 125 mg/5 mL, 250 mg/5 mL
AADA 60–692	Ampicillin Capsules USP (Trihydrate), 250 mg, 500 mg
AADA 60–765	Ampicillin Capsules USP (Trihydrate), 250 mg, 500 mg
AADA 61–183	Ampicillin for Oral Suspension USP, 125 mg/5 mL, 250 mg/5 mL
AADA 61–468	Tetracycline Syrup, 125 mg/5 mL
AADA 62–237	Erythromycin Estolate Capsules USP, 250 mg
AADA 62–762	Cephradine Capsules USP, 250 mg, 500 mg
ANDA 70–360	Diazepam Tablets USP, 2 mg
ANDA 70–361	Diazepam Tablets USP, 5 mg
ANDA 70–362	Diazepam Tablets USP, 10 mg
ANDA 70–935	Perphenazine and Amitriptyline HCl Tablets USP, 2 mg/10 mg
ANDA 70–936	Perphenazine and Amitriptyline HCl Tablets USP, 2 mg/25 mg
ANDA 70–937	Perphenazine and Amitriptyline HCl Tablets USP, 4 mg/10 mg
ANDA 70–938	Perphenazine and Amitriptyline HCl Tablets USP, 4 mg/25 mg
ANDA 70–939	Perphenazine and Amitriptyline HCl Tablets USP, 4 mg/50 mg
ANDA 71–154	Ibuprofen Tablets USP, 200 mg (Round)
ANDA 71–458	Methyldopa and Hydrochlorothiazide Tablets USP, 250 mg/15 mg
ANDA 71–459	Methyldopa and Hydrochlorothiazide Tablets USP, 250 mg/25 mg
ANDA 71–460	Methyldopa and Hydrochlorothiazide Tablets USP, 500 mg/30 mg
ANDA 71–461	Methyldopa and Hydrochlorothiazide Tablets USP, 500 mg/50 mg
ANDA 71–552	Propranolol HCl and Hydrochlorothiazide Tablets USP, 40 mg/25 mg
ANDA 71–553	Propranolol HCl and Hydrochlorothiazide Tablets USP, 80 mg/25 mg
ANDA 72–040	Ibuprofen Tablets USP, 200 mg (Caplet)
ANDA 72–063	Propranolol HCl Tablets USP, 10 mg
ANDA 72–066	Propranolol HCl Tablets USP, 20 mg
ANDA 72–067	Propranolol HCl Tablets USP, 40 mg
ANDA 72–068	Propranolol HCl Tablets USP, 60 mg
ANDA 72–069	Propranolol HCl Tablets USP, 80 mg
ANDA 80–078	Nitrofurantoin Tablets (Microcrystalline) 50 mg, 100 mg
ANDA 80–143	Trisulfapyrimidines Tablets USP
ANDA 80–215	Propylthiouracil Tablets USP, 50 mg
ANDA 80–270	Isoniazid Tablets USP, 100 mg
ANDA 80–283	Prednisone Tablets USP, 5 mg
ANDA 80–378	Prednisolone Tablets USP, 5 mg
ANDA 80–630	Cortisone Acetate Tablets USP, 25 mg
ANDA 80–735	Dimenhydrinate Tablets USP, 50 mg
ANDA 80–762	Diphenhydramine HCl Capsules USP, 25 mg, 50 mg
ANDA 80–779	Chlorphenirarnine Maleate Tablets USP, 4 mg
ANDA 83–035	Vitamin A Capsules USP, 50,000 units
ANDA 83–077	Propoxyphene Compound Capsules